Companies To Watch: Hummingbird Bioscience
By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein
Joining the forces of computation and systems biology to fight cancer and autoimmune disease
Hummingbird Bioscience has built its own platform, dubbed Rational Antibody Discovery (RAD), to discover a pipeline of precision therapeutics under development for treating cancer and autoimmune diseases. RAD combines AI tools and systems biology that guide the creation of antibodies to bind with critical functional regions of the proteins triggering disease. The platform has yielded three different agents for solid tumors and one targeting autoimmunity and cancer. Two lead drugs, coded HMBD-001 and HMBD-002, are in Phase 1 trials for solid tumors. Two other cancer drugs, HMBD-501 and HMBD-011, have entered preclinical testing, and two earlier- stage programs are in discovery.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.